

## Details on abstracts listed above and additional key abstracts for Merck

<b>Bladder cancer</b>	
Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, Phase 3 KEYNOTE-B15 study. M. D. Galsky. <sup>1</sup>	Abstract #LBA630, Oral abstract session B: Urothelial carcinoma
Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (pembro) in participants (Pts) with advanced urothelial carcinoma (UC): Results from the Phase 2 2870-002/SKB264-II-06 study. X. Bian. <sup>3</sup>	Abstract #744, Poster session B: Prostate cancer and urothelial carcinoma
Pathological outcomes and disease-free survival (DFS) in KEYNOTE-905: Neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible. To be determined. <sup>1</sup>	Abstract #638, Rapid oral abstract session B: Urothelial carcinoma
KEYMAKER-U04 substudy 04B: First-line (1L) enfortumab vedotin (EV) plus pembrolizumab (pembro)-based immune checkpoint inhibitor (ICI) combinations for advanced urothelial cancer (UC). A. Peer. <sup>1</sup>	Abstract #634, Rapid oral abstract session B: Urothelial carcinoma
SWOG 2427: Single arm Phase II study of bladder preservation with immunoradiotherapy after a clinically meaningful response to neoadjuvant therapy in patients with muscle invasive bladder cancer (BRIGHT). L. K. Ballas. <sup>4</sup>	Abstract #TPS913, Trials in progress poster session B: Urothelial carcinoma
<b>Kidney cancer</b>	
Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): The randomized Phase 3 LITESPARK-022 study. T. K. Choueiri.	Abstract #LBA418, Oral abstract session C: Renal cell cancer and testicular cancer
Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti-PD-(L)1 therapy: Open-label Phase 3 LITESPARK-011 study. R. J. Motzer. <sup>2</sup>	Abstract #LBA417, Oral abstract session C: Renal cell cancer and testicular cancer
Ascending dose escalation of belzutifan plus palbociclib for previously treated advanced clear cell renal cell carcinoma (ccRCC): Phase 1/2 LITESPARK-024 study Part 1. D. F. McDermott. <sup>5</sup>	Abstract #423, Rapid oral abstract session C: Renal cell cancer and testicular cancer
KEYMAKER-U03 substudy 03B: Novel investigative regimens for previously treated advanced clear cell renal cell carcinoma (ccRCC). L. Albiges.	Abstract #505, Poster session C: Renal cell cancer; adrenal, penile, testicular and urethral cancers
Phase 2 trial of belzutifan in participants from China and Japan with von Hippel-Lindau disease-associated tumors: Results from LITESPARK-015 cohort B1. G. Naik.	Abstract #494, Poster session C: Renal cell cancer; adrenal, penile, testicular and urethral cancers
<b>Prostate cancer</b>	
Efficacy and safety of the DLL3 T-cell engager gocatamig in participants (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN). H. Beltran. <sup>6</sup>	Abstract #182, Poster session A: Prostate cancer

<sup>1</sup> In collaboration with Astellas/Pfizer

<sup>2</sup> In collaboration with Eisai

<sup>3</sup> Led by Kelun-Biotech, conducted in China

<sup>4</sup> Sponsored by National Cancer Institute

<sup>5</sup> In collaboration with Pfizer

<sup>6</sup> In collaboration with Daiichi Sankyo